Global Sourcing Of Materials And Technologies For Car-T Therapy Commercialization
- What does the global development and production network for cell therapies look like at Celgene?
- Creating an ecosystem of capabilities by building a production network, including outsourcing operations
- Examining Celgene’s leading CAR-T development programs for bb2121 and JCAR017
- Discussing the differences between a traditional biopharma vs. autologous cell therapy supply chain
- Qualifying supply continuity and quality risks to create proposed mitigations
- Developing suppliers by proactively sharing requirements and encouraging investment in materials and equipment that is fit for purpose
- Engaging in strategic supplier partnerships